Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Short term Debt (2020 - 2021)

Tg Therapeutics (TGTX) has 2 years of Short term Debt data on record, last reported at $975000.0 in Q4 2021.

  • For Q4 2021, Short term Debt fell 95.6% year-over-year to $975000.0; the TTM value through Dec 2021 reached $975000.0, down 95.6%, while the annual FY2021 figure was $975000.0, 95.6% down from the prior year.
  • Short term Debt reached $975000.0 in Q4 2021 per TGTX's latest filing, down from $16.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $30.1 million in Q1 2021 and bottomed at $975000.0 in Q4 2021.